Cardinal Health (CAH) has raised its fiscal 2024 guidance range for non-GAAP earnings per share to $6.75 to $7.00, from prior guidance range of $6.50 to $6.75. The guidance includes an update to the Pharmaceutical segment profit outlook to 7% to 9% growth, from prior guidance range of 4% to 6% growth. Pharmaceutical segment revenue growth is projected in a range of 10% to 12%.
For the fiscal 2024-26 period, Cardinal Health targets non-GAAP EPS growth of 12% to 14%, CAGR.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com